Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients

This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Serum Aortic Valve Sclerosis Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Heart Diseases Lipoprotein(a) Myocardial Ischemia Severity Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Sohag University

Sohag, 82511, Egypt

About this study

Aortic valve sclerosis (AVS) has a prevalence of 2% to 7% in the population above 65 years of age. In industrialized countries, aortic valve sclerosis is most frequently caused by progressive calcification and degeneration of the aortic cusps.

Coronary artery disease (CAD) is the most significant single cause of death in the world. In developed countries, more than 25% of all deaths in persons older than 35 years are due to CAD. More than half of acute myocardial infarctions occur without previous history or symptoms of CAD.

In recent years, there has been a special emphasis on lipoprotein(a) (Lp(a)), a significant, causal, and nonmodifiable predictor of valvular outcomes and CAD in the general population

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age ≥ 18 years.
Both sexes.
Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.

Exclusion criteria

Aortic stenosis.
Aortic prosthesis.
Untreated hypothyroidism.
Severe chronic kidney failure.
Administration of anti-inflammatory or immunosuppressive drugs.
Pregnancy.

Treatment and study plan

Serum Lipoprotein-a level

Other

A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.

Primary outcomes

Incidence of significance of coronary lesions

Time frame: 1 month post-procedure

Incidence of significance of coronary lesions in relation to lipoprotein (a) level was recorded.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Official study title

Is Lipoprotein-a Just a Lipid Marker or a Predictor for the Severity of Coronary Lesions in Aortic Valve Sclerosis Patients?

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Oct 7, 2025
Registry last updated: Oct 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed